What is the recommended treatment for a 26-year-old male with acute pericarditis presenting with sternal chest pain radiating to the right latissimus dorsi, worsened by inspiration, relieved by leaning forward, and sinus arrhythmia on ECG?

Treatment of Acute Pericarditis in a Young Adult

Initiate combination therapy with high-dose NSAIDs (aspirin 750–1000 mg every 8 hours OR ibuprofen 600 mg every 8 hours) PLUS colchicine (0.5 mg once daily if <70 kg or 0.5 mg twice daily if ≥70 kg) PLUS gastroprotection for 1–2 weeks, with treatment duration and tapering guided by symptom resolution and CRP normalization. 1

Clinical Presentation Analysis

This 26-year-old male presents with classic acute pericarditis features:

• Pleuritic chest pain (sternal pain worsened by inhalation) that is positional (relieved by leaning forward) 2, 3
• Pain radiating to the trapezius ridge (right latissimus dorsi region) 2
• Sinus arrhythmia on ECG (a benign finding that does not alter management) 2

The clinical presentation strongly suggests idiopathic or presumed viral pericarditis, which accounts for most cases in North America and Western Europe and carries an excellent prognosis with appropriate treatment. 2, 3

Risk Stratification and Disposition

This patient appears to be LOW RISK based on the information provided, assuming absence of:

• High fever >38°C
• Subacute onset over several days
• Large pericardial effusion (>20 mm diastolic echo-free space)
• Cardiac tamponade
• Immunosuppression
• Trauma or anticoagulant use 1, 4

Outpatient management is appropriate for low-risk patients without major or minor risk factors. 1, 4

First-Line Pharmacologic Treatment

NSAID Therapy (Class I, Level A Recommendation)

Choose ONE of the following NSAIDs: 1

• Aspirin 750–1000 mg every 8 hours (preferred if patient has cardiovascular disease requiring antiplatelet therapy) 1
• Ibuprofen 600 mg every 8 hours (alternative option) 1

Duration: Continue for 1–2 weeks until symptoms resolve and CRP normalizes. 1

Tapering: Reduce aspirin by 250–500 mg every 1–2 weeks OR ibuprofen by 200–400 mg every 1–2 weeks. 1

Colchicine (Class I, Level A Recommendation)

Mandatory adjunctive therapy to improve response and prevent recurrence (reduces recurrence from 37.5% to 16.7%, absolute risk reduction 20.8%). 1, 2

Dosing: 1, 4

• 0.5 mg once daily if patient weighs <70 kg
• 0.5 mg twice daily if patient weighs ≥70 kg

Duration: Continue for 3 months for first episode of acute pericarditis. 1, 4

Tapering: Not mandatory, but may consider 0.5 mg every other day (<70 kg) or 0.5 mg once daily (≥70 kg) in final weeks. 1

Gastroprotection (Class I, Level A Recommendation)

Proton pump inhibitor (e.g., omeprazole 20–40 mg daily) must be provided with NSAID therapy. 1, 4

Monitoring and Follow-Up

Serial CRP measurements should guide treatment duration and assess therapeutic response. 1, 4

• Continue NSAIDs until CRP normalizes 1
• Failure to improve after 7 days warrants hospital admission and etiologic workup 4

Baseline diagnostic workup should include: 4, 3

• Chest X-ray
• Troponin (to assess myocardial involvement)
• CRP
• ECG
• Transthoracic echocardiography (to assess effusion size and exclude tamponade) 3

Activity Restriction

Non-athletes: Restrict physical activity beyond ordinary sedentary life until symptoms resolve AND CRP, ECG, and echocardiogram normalize. 1, 4

Athletes: Avoid competitive sports for at least 3 months after symptom onset, even if clinical recovery occurs earlier. 1, 4

When NOT to Use Corticosteroids

Corticosteroids are NOT recommended as first-line therapy (Class III recommendation) because they promote chronic disease evolution, drug dependence, and increase recurrence risk up to 50%. 1, 4

Reserve low-dose corticosteroids (prednisone 0.2–0.5 mg/kg/day) ONLY for: 1, 4

• Contraindication to NSAIDs/colchicine
• Failure of first-line therapy after adequate trial
• Specific indications (autoimmune disease, pregnancy >20 weeks, renal failure)
• After infectious causes have been excluded 1, 4

Never use high-dose corticosteroids (prednisone 1.0 mg/kg/day). 1, 4

Management of Recurrence

Recurrence occurs in 15–30% of patients not treated with colchicine. 1, 2, 5

If first recurrence develops (defined as symptom-free interval ≥4–6 weeks followed by recurrence): 1, 4

• Restart NSAIDs + colchicine
• Extend colchicine duration to at least 6 months 4
• Consider IL-1 blockers for multiple recurrences refractory to conventional therapy 2, 6

Critical Pitfalls to Avoid

• Do NOT omit colchicine—it is mandatory, not optional, and reduces recurrence by approximately 50%. 1, 2
• Do NOT use corticosteroids as first-line therapy—they worsen long-term outcomes. 1, 4
• Do NOT undertaper NSAIDs too quickly—premature discontinuation increases recurrence risk. 1
• Do NOT ignore CRP monitoring—it is the best biomarker to guide treatment duration. 1, 4
• Do NOT allow premature return to athletics—athletes require minimum 3-month restriction. 1, 4